Ona Therapeutics’ antibody drug conjugates come from a platform technology that discovers novel antigens intended to enable the therapies to overcome drug resistance. The Spain-based startup’s lead ADC is on track to begin clinical testing in breast cancer.
The post Startup Secures $86M to Take On One of the Challenges for ADCs in Breast Cancer appeared first on MedCity News.
